Effect of Diallyl Trisulfide on TNF-α-induced CCL2/MCP-1 Release in Genetically Different Triple-negative Breast Cancer Cells.

Allyl Compounds / pharmacology Apoptosis / drug effects Biomarkers, Tumor / metabolism Cell Line, Tumor Cell Movement / drug effects Cell Survival / drug effects Chemokine CCL2 / biosynthesis Cytokines / biosynthesis Female Gene Expression Regulation, Neoplastic Humans Sulfides / pharmacology Triple Negative Breast Neoplasms / genetics Tumor Necrosis Factor-alpha / metabolism
Breast cancer CCL2 IKBKE MAPK8 MCP-1 diallyl trisulfide tumor necrosis factor alpha

Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
Dec 2021
Historique:
received: 07 09 2021
revised: 28 09 2021
accepted: 04 10 2021
entrez: 1 12 2021
pubmed: 2 12 2021
medline: 15 12 2021
Statut: ppublish

Résumé

Diallyl trisulfide (DATS) has been shown to prevent and inhibit breast carcinogenesis. CCL2/MCP-1 has been shown to play a significant role in breast cancer. This study explored DATS efficacy on triple-negative breast cancer (TNBC) cells. DATS efficacy on TNF-α induced TNBC cells were examined via trypan blue exclusion test, wound-healing assay, human cytokine arrays, ELISA, and RT-PCR. DATS significantly induced cell death and inhibited cell migration. Expression of CCL2/MCP-1, IL-6, PDGF-BB, NT-3, and GM-CSF in TNF-α-treated cells increased. However, DATS significantly decreased the expression of CCL2/MCP-1 in TNF-α-treated MDA-MB-231 but not in MDA-MB-468 cells. DATS significantly down-regulated mRNA expression of IKBKE and MAPK8 in both cell lines, indicating a possible effect in genes involved in the NF-κB and MAPK signaling. DATS may have a role in TNBC therapy and prevention by targeting CCL2.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
Diallyl trisulfide (DATS) has been shown to prevent and inhibit breast carcinogenesis. CCL2/MCP-1 has been shown to play a significant role in breast cancer. This study explored DATS efficacy on triple-negative breast cancer (TNBC) cells.
MATERIALS AND METHODS METHODS
DATS efficacy on TNF-α induced TNBC cells were examined via trypan blue exclusion test, wound-healing assay, human cytokine arrays, ELISA, and RT-PCR.
RESULTS RESULTS
DATS significantly induced cell death and inhibited cell migration. Expression of CCL2/MCP-1, IL-6, PDGF-BB, NT-3, and GM-CSF in TNF-α-treated cells increased. However, DATS significantly decreased the expression of CCL2/MCP-1 in TNF-α-treated MDA-MB-231 but not in MDA-MB-468 cells. DATS significantly down-regulated mRNA expression of IKBKE and MAPK8 in both cell lines, indicating a possible effect in genes involved in the NF-κB and MAPK signaling.
CONCLUSION CONCLUSIONS
DATS may have a role in TNBC therapy and prevention by targeting CCL2.

Identifiants

DOI: 10.21873/anticanres.15411 PMID: 34848446 PMC: PMC8691120
pubmed: 34848446
pii: 41/12/5919
doi: 10.21873/anticanres.15411
pmc: PMC8691120
mid: NIHMS1762576
doi:

Substances chimiques

Allyl Compounds 0
Biomarkers, Tumor 0
CCL2 protein, human 0
Chemokine CCL2 0
Cytokines 0
Sulfides 0
Tumor Necrosis Factor-alpha 0
diallyl trisulfide 0ZO1U5A3XX

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5919-5933

Subventions

Organisme : NIMHD NIH HHS
ID : P20 MD006738
Pays : United States
Organisme : NIMHD NIH HHS
ID : U54 MD007582
Pays : United States

Informations de copyright

Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Références

Immunobiology. 2010 Sep-Oct;215(9-10):737-47
pubmed: 20605053
J Biol Chem. 2012 Oct 19;287(43):36593-608
pubmed: 22927430
Cancer Res. 2006 May 15;66(10):5379-86
pubmed: 16707465
Clin Cancer Res. 2013 Jul 1;19(13):3404-15
pubmed: 23653148
Biochim Biophys Acta. 2010 Oct-Dec;1799(10-12):775-87
pubmed: 20493977
Folia Histochem Cytobiol. 2011;49(2):240-7
pubmed: 21744323
Front Oncol. 2019 May 31;9:456
pubmed: 31214501
Cancer J. 2008 Nov-Dec;14(6):343-51
pubmed: 19060597
J Biol Chem. 2005 Jul 1;280(26):25202-9
pubmed: 15863510
Anticancer Res. 2014 Jun;34(6):2763-70
pubmed: 24922637
JAMA Surg. 2020 May 1;155(5):440-442
pubmed: 32074266
Acta Neuropathol. 1997 May;93(5):518-27
pubmed: 9144591
Antioxidants (Basel). 2019 Apr 16;8(4):
pubmed: 30995775
Am J Clin Oncol. 2010 Dec;33(6):637-45
pubmed: 20023571
Environ Mol Mutagen. 2009 Apr;50(3):266-75
pubmed: 19197990
Breast Cancer Res Treat. 2013 Feb;138(1):69-79
pubmed: 23412769
J Leukoc Biol. 2011 Jan;89(1):31-9
pubmed: 20628066
Eur J Cancer. 2008 Dec;44(18):2799-805
pubmed: 19008097
Cancer. 2007 Sep 1;110(5):1083-95
pubmed: 17647244
PLoS One. 2019 Oct 30;14(10):e0215269
pubmed: 31665136
Cancer Prev Res (Phila). 2010 Nov;3(11):1473-83
pubmed: 20959517
N Engl J Med. 1986 Dec 25;315(26):1650-9
pubmed: 3537791
Front Biosci (Schol Ed). 2019 Mar 1;11:75-88
pubmed: 30844737
Nutr Cancer. 2012;64(7):1112-21
pubmed: 23006051
J Pathol. 1998 Dec;186(4):372-7
pubmed: 10209485
Melanoma Res. 2005 Oct;15(5):417-25
pubmed: 16179869
Nat Rev Cancer. 2009 Apr;9(4):239-52
pubmed: 19279573
Oncogene. 2005 Sep 15;24(41):6256-68
pubmed: 15940258
Nat Immunol. 2002 Mar;3(3):221-7
pubmed: 11875461
J Cell Biochem. 2011 Jan;112(1):118-27
pubmed: 21053278
Nat Rev Drug Discov. 2012 Jun 01;11(6):479-97
pubmed: 22653217
PLoS One. 2009 Jul 03;4(7):e6146
pubmed: 19582160
Cancer Res. 2011 Oct 15;71(20):6400-9
pubmed: 21900394
Biochem Pharmacol. 2013 Apr 1;85(7):873-80
pubmed: 23333767
N Engl J Med. 2010 Nov 11;363(20):1938-48
pubmed: 21067385
Cancer Res. 2003 Jan 15;63(2):290-5
pubmed: 12543776
Cytokine Growth Factor Rev. 2010 Feb;21(1):41-8
pubmed: 20005149
J Agric Food Chem. 2020 Feb 12;68(6):1571-1578
pubmed: 31927886
J Immunother. 2010 Oct;33(8):780-8
pubmed: 20842059
Vet Comp Oncol. 2011 Mar;9(1):55-64
pubmed: 21303454
Clin Exp Metastasis. 2012 Aug;29(6):585-601
pubmed: 22484917
Ann Surg. 2019 Sep;270(3):484-492
pubmed: 31356281
Cell Death Dis. 2018 Aug 29;9(9):880
pubmed: 30158589
Cell Mol Life Sci. 2006 Feb;63(4):449-68
pubmed: 16416030
Cancer Cell. 2019 Apr 15;35(4):588-602.e10
pubmed: 30930117
Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931
Curr Cancer Drug Targets. 2019;19(3):189-198
pubmed: 29952260
PLoS One. 2015 Apr 30;10(4):e0123781
pubmed: 25927362
Cancer. 2007 Jan 1;109(1):25-32
pubmed: 17146782
Oncogene. 1999 Nov 22;18(49):6910-24
pubmed: 10602466
Cancer Biol Ther. 2009 Nov;8(22):2175-85
pubmed: 19823037
Sci STKE. 2006 Oct 17;2006(357):re13
pubmed: 17047224
PLoS One. 2017 Apr 25;12(4):e0175558
pubmed: 28441391
Clin Exp Immunol. 2011 Apr;164(1):57-65
pubmed: 21361908
Oncol Lett. 2017 Sep;14(3):3594-3600
pubmed: 28927117
Anticancer Agents Med Chem. 2011 Mar;11(3):249-53
pubmed: 21269259
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
Cancer Lett. 2008 Aug 28;267(2):271-85
pubmed: 18439751
Expert Opin Pharmacother. 2009 Sep;10(13):2081-93
pubmed: 19640211

Auteurs

Konan J W Kanga (KJW)

Division of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Florida A&M University, Tallahassee, FL, U.S.A.

Patricia Mendonca (P)

Division of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Florida A&M University, Tallahassee, FL, U.S.A.

Karam F A Soliman (KFA)

Division of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Florida A&M University, Tallahassee, FL, U.S.A.

Dominique T Ferguson (DT)

Division of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Florida A&M University, Tallahassee, FL, U.S.A.

Selina F Darling-Reed (SF)

Division of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Florida A&M University, Tallahassee, FL, U.S.A. selina.darling@famu.edu sdarlingreed@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Hydrocarbures acycliques › Alcènes › Composés allyliques › Effect of Diallyl Trisulfide on TNF-α-induced...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Mort cellulaire › Mort cellulaire régulée › Apoptose › Effect of Diallyl Trisulfide on TNF-α-induced...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Effect of Diallyl Trisulfide on TNF-α-induced...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Effect of Diallyl Trisulfide on TNF-α-induced...
questionsmedicales.fr › Phénomènes physiologiques › Mouvement cellulaire › Effect of Diallyl Trisulfide on TNF-α-induced...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Survie cellulaire › Effect of Diallyl Trisulfide on TNF-α-induced...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Chimiokines › Chimiokines CC › Protéines chimioattractives monocytaires › Chimiokine CCL2 › Effect of Diallyl Trisulfide on TNF-α-induced...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Effect of Diallyl Trisulfide on TNF-α-induced...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Régulation de l'expression des gènes tumoraux › Effect of Diallyl Trisulfide on TNF-α-induced...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Effect of Diallyl Trisulfide on TNF-α-induced...
questionsmedicales.fr › Composés chimiques organiques › Composés du soufre › Sulfures › Effect of Diallyl Trisulfide on TNF-α-induced...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › Tumeurs du sein triple-négatives › Effect of Diallyl Trisulfide on TNF-α-induced...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Facteurs de nécrose tumorale › Facteur de nécrose tumorale alpha › Effect of Diallyl Trisulfide on TNF-α-induced...